Chemotherapy regimen for endometrial cancer

The clinical cure rate of patients with early-stage endometrial cancer is relatively milder than that of patients with late-stage endometrial cancer. Through appropriate surgical treatment and some postoperative consolidation treatment measures, a higher clinical cure rate and a better prognosis can be achieved.

However, because the chance of early diagnosis of endometrial cancer is not high, this also limits the chance of early detection and early treatment of endometrial cancer patients. The rapid progression of cancer cells and the rapid worsening of the disease make it relatively difficult to treat patients with advanced endometrial cancer, and the cure rate of endometrial cancer is greatly reduced.

The key to improving the cure rate of endometrial cancer is to pay attention to the treatment method. Since most patients with endometrial cancer are in the advanced stage when clinically diagnosed, their condition is more serious at this time. Traditional treatment methods for endometrial cancer, such as surgery, radiotherapy and chemotherapy, cannot achieve ideal therapeutic effects. Surgery is only a local treatment method to remove local tumor tissue, but surgery is more traumatic and is prone to a series of complications after surgery. For patients with advanced endometrial cancer who have poor physical constitution and serious condition, they may not be able to tolerate it and it is difficult for them to recover as soon as possible after surgery. Therefore, in order to improve the cure rate of endometrial cancer in patients with advanced endometrial cancer, surgical treatment should be used with caution.

Some endometrial cancer patients may not be able to tolerate the side effects of radiotherapy and chemotherapy. Many toxic and side effects will occur after radiotherapy and chemotherapy for endometrial cancer, which will cause a decrease in human immunity. Therefore, for patients with advanced endometrial cancer and poor physical condition, 1-3 courses of radiotherapy and chemotherapy should be given to the patients according to their actual situation. The efficacy of radiotherapy and chemotherapy should be evaluated in time, and the radiotherapy and chemotherapy plan should be adjusted in time according to the patient's physical condition, and the radiotherapy and chemotherapy plan should be terminated if necessary.

In view of this, the clinic often recommends combining supportive treatment to improve the immunity of advanced patients with autologous cell immunotherapy. Autologous cell immunotherapy is to use one's own cells to treat one's own cancer. It achieves the purpose and effect of inhibiting and killing cancer cells in the body by improving the activity of the body's own immune cells, regulating and enhancing the body's autonomous anti-cancer immune ability. Autologous cell immunotherapy can be applied to all stages of endometrial cancer. It can effectively control the patient's condition, prevent the recurrence and metastasis of cancer cells, and inhibit tumor immune escape. At the same time, it can also effectively improve the body's autonomous anti-cancer immune ability, stimulate the body's immune response, improve the overall treatment effect, improve the patient's overall physical condition, and effectively achieve the goal of improving the quality of life of endometrial cancer patients and prolonging the patient's survival period, greatly improving the cure rate of endometrial cancer.